Charles River Laboratories stock (US1591881009): Insider grant and fresh fund buying keep focus on CRL

Charles River Laboratories shares remain in focus after a new director equity grant and a fresh position disclosed by 1492 Capital Management, while the US-listed stock continues to trade actively on the NYSE.

Charles River Laboratories remains on investors' radar after a recent insider equity award to a board member and a fresh institutional position reported by 1492 Capital Management, underscoring ongoing interest in the US-based contract research specialist.

According to NYSE data cited by MarketBeat in an article dated 06/04/2026, Charles River Laboratories International stock opened at USD 180.10 on the New York Stock Exchange under the ticker CRL on that day, highlighting continued liquidity in its home US market.MarketBeat as of 06/04/2026

In a regulatory Form 4 filing summarized by StockTitan on 05/27/2026, Charles River Laboratories director Steven Barg was granted 422 restricted stock units of the company’s common stock at a reference price of USD 174.79 per share in lieu of cash director service fees for the term beginning 05/05/2026.StockTitan as of 05/27/2026

The same StockTitan summary notes that following this award, Barg’s direct holdings increased to 3,287 shares of Charles River Laboratories, with the restricted stock units scheduled to vest on the earlier of 06/02/2027 or the business day before the company’s next annual meeting of shareholders, reinforcing that this is a routine compensation-related transaction rather than an open-market purchase.StockTitan as of 05/27/2026

As of 06/04/2026, the stock continues to trade on the NYSE in USD, confirming that Charles River Laboratories remains actively listed in its home market in the United States, with no completed take-private or delisting transaction reported by the exchange or the US Securities and Exchange Commission in recent months.

As of: 04.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Charles River Labs
• Sector/industry: Contract research and laboratory services for biopharmaceutical and biotech clients
• Headquarters/country: Wilmington, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Preclinical research services, safety assessment, discovery and development support for pharmaceutical and biotechnology companies
• Home exchange/listing venue: New York Stock Exchange (CRL)
• Trading currency: USD

Charles River Laboratories: core business model

Charles River Labs operates as a global contract research partner, providing specialized laboratory and preclinical services that help pharmaceutical and biotechnology companies move drug candidates from discovery through early-stage development, with revenues largely generated from fee-based research projects and long-term service relationships.

Industry trends and competitive position

The broader contract research and laboratory services market continues to benefit from the trend of pharmaceutical and biotechnology companies outsourcing non-core functions, as they seek to manage R&D costs and accelerate development timelines by relying on specialized external partners.

Within this landscape, Charles River Laboratories competes with other global research and laboratory providers, positioning itself as an integrated preclinical and early-development specialist able to support complex programs across multiple therapeutic areas for clients in the United States and internationally.

Conclusion

The latest insider restricted stock unit grant to director Steven Barg and the reported position by 1492 Capital Management highlight that Charles River Laboratories continues to attract attention from both corporate insiders and institutional investors.

Set against an expanding global market for outsourced research and laboratory services, the company’s active NYSE listing and ongoing capital markets activity keep the stock relevant for market participants monitoring developments in the contract research space.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.